<_value> Research Axed on Tolerance of BIOtherapies RATIO FRESH-PEF6829-en 6829 FRESH-PEF6829 Xavier MARIETTE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP) AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (ANSM) Epidemiology France Portal (PEF) ABBOTT FRANCE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) MERCK SANTE PFIZER (FRANCE) null Xavier;MARIETTE CNIL Anti-TNF-alpha tolerance Endocrinology Infectious disease medicine Certain infectious or parasitic diseases Healthcare system determinants: Use of care Healthcare system determinants To describe cases of opportunistic infection, severe bacterial infection and lymphoma in patients who are receiving or have received anti-TNF-alpha therapy. null France Individuals Patients population Male Female Child (6 to 12 years) Adolescent (13 to 18 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Men or women - receiving or have received anti-TNFα therapy Clinical data Health event/morbidity Health care consumption and services Other >= 20000 individuals Converting or copying information into a structured record Observational Study Observational Study Morbidity registry 57 711 par an / by year Unknown Restricted access Contact the principal investigator Access on specific project only